| Characteristic . | ICPP Group, n = 140 . | NCCAH Group, n = 37 . | . | ||
|---|---|---|---|---|---|
| Mean ± SD . | Range . | Mean ± SD . | Range . | P . | |
| Clinical feature | |||||
| Age at onset, y | 6.96 ± 1.14 | 1.5–8.8 | 7.2 ± 0.8 | 4.5–8.3 | 0.34 |
| Age at diagnosis, y | 7.54 ± 1.1 | 3.3–9.5 | 7.6 ± 1.1 | 4.6–9 | 0.85 |
| Pubarche, %a | 27.3, 59, 9.4, 4.3, 0 | 5.6, 72.2, 22.2, 0, 0 | 0.007 | ||
| Thelarche, %a | 0, 54.3, 41.4, 4.3, 0 | 0, 83.8, 16.2, 0, 0 | 0.004 | ||
| Axillary hair, %a | 59.3, 37.1, 2.9, 0, 0 | 61.1, 30.6, 8.3, 0, 0 | 0.43 | ||
| Anthropometric measurement | |||||
| Height SDS | 0.69 ± 1.09 | −2.6 to 4.37 | 0.52 ± 0.82 | −1.16 to 2.22 | 0.37 |
| Weight SDS | 0.93 ± 0.90 | −2to 2.81 | 0.68 ± 1.06 | −1.7 to 2.3 | 0.16 |
| BMI SDS | 0.87 ± 0.86 | −2.14 to 2.43 | 0.55 ± 1.19 | −2.75 to 2.32 | 0.07 |
| BA, y | 9.03 ± 1.53 | 4.5–12.5 | 9.28 ± 1.71 | 3.5–11.5 | 0.39 |
| BA − chronological age, y | 1.48 ± 1.07 | −0.93 to 5.1 | 1.7 ± 1.04 | −1.17 to 3.83 | 0.29 |
| Hormonal profile | |||||
| Estradiol, pmol/L | 49.16 ± 55.54 | 3–212.5 | 54.35 ± 35.88 | 2.4–116.6 | 0.78 |
| DHEAS, μmol/L | 1.5 ± 1.23 | 0.3–6.7 | 3.6 ± 2.23 | 0.6–10.26 | <0.001 |
| Androstenedione, nmol/L | 2.15 ± 2.26 | 0.1–22 | 5.01 ± 4.18 | 0.04–23.6 | <0.001 |
| Basal LH, IU/L | 0.62 ± 0.77 | 0.08–4.4 | 0.52 ± 0.59 | 0.08–1.9 | 0.49 |
| Stimulated LH, IU/L | 13.23 ± 13.55 | 0.3–68.4 | 4.77 ± 3.7 | 0.08–15.7 | <0.002 |
| Basal FSH, IU/L | 3.23 ± 1.98 | 0.13–9.4 | 2.57 ± 2.51 | 0.9–10.9 | 0.1 |
| Stimulated FSH, IU/L | 10.40 ± 4.54 | 1.09–30.7 | 7.92 ± 3.26 | 2.3–13.4 | 0.008 |
| Basal 17-OHP, nmol/L | 1.86 ± 1.291 | 0.3–9.6 | 32.62 ± 26.66 | 2.2–96 | <0.001 |
| Stimulated 17-OHP, nmol/L | 7.2 ± 3.2 | 2–22.7 | 123.6 ± 47.1 | 28.5–203 | <0.001 |
| Basal cortisol, nmol/L | 262.9 ± 125.4 | 68–629 | 306.8 ± 153.5 | 114–646 | 0.08 |
| Stimulated cortisol, nmol/L | 697.6 ± 97 | 419–1046 | 550.7 ± 140.9 | 340–899 | <0.001 |
| Characteristic . | ICPP Group, n = 140 . | NCCAH Group, n = 37 . | . | ||
|---|---|---|---|---|---|
| Mean ± SD . | Range . | Mean ± SD . | Range . | P . | |
| Clinical feature | |||||
| Age at onset, y | 6.96 ± 1.14 | 1.5–8.8 | 7.2 ± 0.8 | 4.5–8.3 | 0.34 |
| Age at diagnosis, y | 7.54 ± 1.1 | 3.3–9.5 | 7.6 ± 1.1 | 4.6–9 | 0.85 |
| Pubarche, %a | 27.3, 59, 9.4, 4.3, 0 | 5.6, 72.2, 22.2, 0, 0 | 0.007 | ||
| Thelarche, %a | 0, 54.3, 41.4, 4.3, 0 | 0, 83.8, 16.2, 0, 0 | 0.004 | ||
| Axillary hair, %a | 59.3, 37.1, 2.9, 0, 0 | 61.1, 30.6, 8.3, 0, 0 | 0.43 | ||
| Anthropometric measurement | |||||
| Height SDS | 0.69 ± 1.09 | −2.6 to 4.37 | 0.52 ± 0.82 | −1.16 to 2.22 | 0.37 |
| Weight SDS | 0.93 ± 0.90 | −2to 2.81 | 0.68 ± 1.06 | −1.7 to 2.3 | 0.16 |
| BMI SDS | 0.87 ± 0.86 | −2.14 to 2.43 | 0.55 ± 1.19 | −2.75 to 2.32 | 0.07 |
| BA, y | 9.03 ± 1.53 | 4.5–12.5 | 9.28 ± 1.71 | 3.5–11.5 | 0.39 |
| BA − chronological age, y | 1.48 ± 1.07 | −0.93 to 5.1 | 1.7 ± 1.04 | −1.17 to 3.83 | 0.29 |
| Hormonal profile | |||||
| Estradiol, pmol/L | 49.16 ± 55.54 | 3–212.5 | 54.35 ± 35.88 | 2.4–116.6 | 0.78 |
| DHEAS, μmol/L | 1.5 ± 1.23 | 0.3–6.7 | 3.6 ± 2.23 | 0.6–10.26 | <0.001 |
| Androstenedione, nmol/L | 2.15 ± 2.26 | 0.1–22 | 5.01 ± 4.18 | 0.04–23.6 | <0.001 |
| Basal LH, IU/L | 0.62 ± 0.77 | 0.08–4.4 | 0.52 ± 0.59 | 0.08–1.9 | 0.49 |
| Stimulated LH, IU/L | 13.23 ± 13.55 | 0.3–68.4 | 4.77 ± 3.7 | 0.08–15.7 | <0.002 |
| Basal FSH, IU/L | 3.23 ± 1.98 | 0.13–9.4 | 2.57 ± 2.51 | 0.9–10.9 | 0.1 |
| Stimulated FSH, IU/L | 10.40 ± 4.54 | 1.09–30.7 | 7.92 ± 3.26 | 2.3–13.4 | 0.008 |
| Basal 17-OHP, nmol/L | 1.86 ± 1.291 | 0.3–9.6 | 32.62 ± 26.66 | 2.2–96 | <0.001 |
| Stimulated 17-OHP, nmol/L | 7.2 ± 3.2 | 2–22.7 | 123.6 ± 47.1 | 28.5–203 | <0.001 |
| Basal cortisol, nmol/L | 262.9 ± 125.4 | 68–629 | 306.8 ± 153.5 | 114–646 | 0.08 |
| Stimulated cortisol, nmol/L | 697.6 ± 97 | 419–1046 | 550.7 ± 140.9 | 340–899 | <0.001 |
Abbreviation: BMI, body mass index.
Tanner stages 1–5.
| Characteristic . | ICPP Group, n = 140 . | NCCAH Group, n = 37 . | . | ||
|---|---|---|---|---|---|
| Mean ± SD . | Range . | Mean ± SD . | Range . | P . | |
| Clinical feature | |||||
| Age at onset, y | 6.96 ± 1.14 | 1.5–8.8 | 7.2 ± 0.8 | 4.5–8.3 | 0.34 |
| Age at diagnosis, y | 7.54 ± 1.1 | 3.3–9.5 | 7.6 ± 1.1 | 4.6–9 | 0.85 |
| Pubarche, %a | 27.3, 59, 9.4, 4.3, 0 | 5.6, 72.2, 22.2, 0, 0 | 0.007 | ||
| Thelarche, %a | 0, 54.3, 41.4, 4.3, 0 | 0, 83.8, 16.2, 0, 0 | 0.004 | ||
| Axillary hair, %a | 59.3, 37.1, 2.9, 0, 0 | 61.1, 30.6, 8.3, 0, 0 | 0.43 | ||
| Anthropometric measurement | |||||
| Height SDS | 0.69 ± 1.09 | −2.6 to 4.37 | 0.52 ± 0.82 | −1.16 to 2.22 | 0.37 |
| Weight SDS | 0.93 ± 0.90 | −2to 2.81 | 0.68 ± 1.06 | −1.7 to 2.3 | 0.16 |
| BMI SDS | 0.87 ± 0.86 | −2.14 to 2.43 | 0.55 ± 1.19 | −2.75 to 2.32 | 0.07 |
| BA, y | 9.03 ± 1.53 | 4.5–12.5 | 9.28 ± 1.71 | 3.5–11.5 | 0.39 |
| BA − chronological age, y | 1.48 ± 1.07 | −0.93 to 5.1 | 1.7 ± 1.04 | −1.17 to 3.83 | 0.29 |
| Hormonal profile | |||||
| Estradiol, pmol/L | 49.16 ± 55.54 | 3–212.5 | 54.35 ± 35.88 | 2.4–116.6 | 0.78 |
| DHEAS, μmol/L | 1.5 ± 1.23 | 0.3–6.7 | 3.6 ± 2.23 | 0.6–10.26 | <0.001 |
| Androstenedione, nmol/L | 2.15 ± 2.26 | 0.1–22 | 5.01 ± 4.18 | 0.04–23.6 | <0.001 |
| Basal LH, IU/L | 0.62 ± 0.77 | 0.08–4.4 | 0.52 ± 0.59 | 0.08–1.9 | 0.49 |
| Stimulated LH, IU/L | 13.23 ± 13.55 | 0.3–68.4 | 4.77 ± 3.7 | 0.08–15.7 | <0.002 |
| Basal FSH, IU/L | 3.23 ± 1.98 | 0.13–9.4 | 2.57 ± 2.51 | 0.9–10.9 | 0.1 |
| Stimulated FSH, IU/L | 10.40 ± 4.54 | 1.09–30.7 | 7.92 ± 3.26 | 2.3–13.4 | 0.008 |
| Basal 17-OHP, nmol/L | 1.86 ± 1.291 | 0.3–9.6 | 32.62 ± 26.66 | 2.2–96 | <0.001 |
| Stimulated 17-OHP, nmol/L | 7.2 ± 3.2 | 2–22.7 | 123.6 ± 47.1 | 28.5–203 | <0.001 |
| Basal cortisol, nmol/L | 262.9 ± 125.4 | 68–629 | 306.8 ± 153.5 | 114–646 | 0.08 |
| Stimulated cortisol, nmol/L | 697.6 ± 97 | 419–1046 | 550.7 ± 140.9 | 340–899 | <0.001 |
| Characteristic . | ICPP Group, n = 140 . | NCCAH Group, n = 37 . | . | ||
|---|---|---|---|---|---|
| Mean ± SD . | Range . | Mean ± SD . | Range . | P . | |
| Clinical feature | |||||
| Age at onset, y | 6.96 ± 1.14 | 1.5–8.8 | 7.2 ± 0.8 | 4.5–8.3 | 0.34 |
| Age at diagnosis, y | 7.54 ± 1.1 | 3.3–9.5 | 7.6 ± 1.1 | 4.6–9 | 0.85 |
| Pubarche, %a | 27.3, 59, 9.4, 4.3, 0 | 5.6, 72.2, 22.2, 0, 0 | 0.007 | ||
| Thelarche, %a | 0, 54.3, 41.4, 4.3, 0 | 0, 83.8, 16.2, 0, 0 | 0.004 | ||
| Axillary hair, %a | 59.3, 37.1, 2.9, 0, 0 | 61.1, 30.6, 8.3, 0, 0 | 0.43 | ||
| Anthropometric measurement | |||||
| Height SDS | 0.69 ± 1.09 | −2.6 to 4.37 | 0.52 ± 0.82 | −1.16 to 2.22 | 0.37 |
| Weight SDS | 0.93 ± 0.90 | −2to 2.81 | 0.68 ± 1.06 | −1.7 to 2.3 | 0.16 |
| BMI SDS | 0.87 ± 0.86 | −2.14 to 2.43 | 0.55 ± 1.19 | −2.75 to 2.32 | 0.07 |
| BA, y | 9.03 ± 1.53 | 4.5–12.5 | 9.28 ± 1.71 | 3.5–11.5 | 0.39 |
| BA − chronological age, y | 1.48 ± 1.07 | −0.93 to 5.1 | 1.7 ± 1.04 | −1.17 to 3.83 | 0.29 |
| Hormonal profile | |||||
| Estradiol, pmol/L | 49.16 ± 55.54 | 3–212.5 | 54.35 ± 35.88 | 2.4–116.6 | 0.78 |
| DHEAS, μmol/L | 1.5 ± 1.23 | 0.3–6.7 | 3.6 ± 2.23 | 0.6–10.26 | <0.001 |
| Androstenedione, nmol/L | 2.15 ± 2.26 | 0.1–22 | 5.01 ± 4.18 | 0.04–23.6 | <0.001 |
| Basal LH, IU/L | 0.62 ± 0.77 | 0.08–4.4 | 0.52 ± 0.59 | 0.08–1.9 | 0.49 |
| Stimulated LH, IU/L | 13.23 ± 13.55 | 0.3–68.4 | 4.77 ± 3.7 | 0.08–15.7 | <0.002 |
| Basal FSH, IU/L | 3.23 ± 1.98 | 0.13–9.4 | 2.57 ± 2.51 | 0.9–10.9 | 0.1 |
| Stimulated FSH, IU/L | 10.40 ± 4.54 | 1.09–30.7 | 7.92 ± 3.26 | 2.3–13.4 | 0.008 |
| Basal 17-OHP, nmol/L | 1.86 ± 1.291 | 0.3–9.6 | 32.62 ± 26.66 | 2.2–96 | <0.001 |
| Stimulated 17-OHP, nmol/L | 7.2 ± 3.2 | 2–22.7 | 123.6 ± 47.1 | 28.5–203 | <0.001 |
| Basal cortisol, nmol/L | 262.9 ± 125.4 | 68–629 | 306.8 ± 153.5 | 114–646 | 0.08 |
| Stimulated cortisol, nmol/L | 697.6 ± 97 | 419–1046 | 550.7 ± 140.9 | 340–899 | <0.001 |
Abbreviation: BMI, body mass index.
Tanner stages 1–5.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
